Breaking News

Macrocyclics, Roche in Nuclear Medicine Pact

May 24, 2013

Aims to speed up the clinical development process

Macrocyclics has entered a new collaborative research agreement with Roche for the continued development of novel chelating agents designed by Macrocyclics for Roche's applications. The collaboration aims to speed up the clinical development process. The new project will build on established progress related to lead-212 (212Pb) and novel chelate architecture for radioimmunotherapy. 
 
"We are privileged to be working with the world leader in oncology and antibody technology and are excited to contribute in the development of powerful new therapies based on lead-212," said Garry Kiefer, chief executive officer of Macrocyclics.

Related Contract Manufacturing:

  • CROs and Today’s  R&D Landscape

    CROs and Today’s R&D Landscape

    Kristin Brooks, Associate Editor, Contract Pharma||November 9, 2016
    John Lewis of ACRO discusses opportunities, challenges, and the future CRO

  • The Human Parts of Mouse Models

    The Human Parts of Mouse Models

    Julia Schueler, Head of in vivo Operations, Oncotest, a Charles River company ||October 11, 2016
    The PDX model system has come back into focus

  • Robust Assay Designs

    Robust Assay Designs

    Tim Wright, Editor, Contract Pharma||October 11, 2016
    Easing the transition from preclinical to clinical research